LoQus23 Therapeutics

September ended and October began with an explosion of new venture capital available for biotech companies, raising expectations for VC fundraising by drug developers through the rest of 2024, especia

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Cidara Hopes For Early 2023 Approval Of

Coming off clinical development setbacks, including a failed effort to expand Ingrezza’s label into pediatric Tourette’s syndrome, Neurocrine Biosciences, Inc. reported positive R&D news to its share

Hopes of a breakthrough in Huntington’s disease have been dashed a number of times, not least this year, but the emergence from stealth mode of a UK biotech backed by Novartis AG 's venture arm could